- Home
- TENX vs LGVN Comparison
TENX vs LGVN Comparison
Compare TENX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- LGVN
- Stock Information
- Founded
- TENX 1967
- LGVN 2014
- Country
- TENX United States
- LGVN United States
- Employees
- TENX N/A
- LGVN N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- TENX Health Care
- LGVN Health Care
- Exchange
- TENX Nasdaq
- LGVN Nasdaq
- Market Cap
- TENX 25.8M
- LGVN 23.4M
- IPO Year
- TENX N/A
- LGVN 2021
- Fundamental
- Price
- TENX $5.84
- LGVN $0.68
- Analyst Decision
- TENX Strong Buy
- LGVN Strong Buy
- Analyst Count
- TENX 3
- LGVN 3
- Target Price
- TENX $16.00
- LGVN $8.67
- AVG Volume (30 Days)
- TENX 23.2K
- LGVN 717.5K
- Earning Date
- TENX 08-19-2025
- LGVN 08-13-2025
- Dividend Yield
- TENX N/A
- LGVN N/A
- EPS Growth
- TENX N/A
- LGVN N/A
- EPS
- TENX N/A
- LGVN N/A
- Revenue
- TENX N/A
- LGVN $2,225,000.00
- Revenue This Year
- TENX N/A
- LGVN N/A
- Revenue Next Year
- TENX N/A
- LGVN $51.48
- P/E Ratio
- TENX N/A
- LGVN N/A
- Revenue Growth
- TENX N/A
- LGVN 127.50
- 52 Week Low
- TENX $3.25
- LGVN $0.63
- 52 Week High
- TENX $7.89
- LGVN $2.86
- Technical
- Relative Strength Index (RSI)
- TENX 39.80
- LGVN 22.13
- Support Level
- TENX $5.80
- LGVN $0.63
- Resistance Level
- TENX $6.25
- LGVN $1.75
- Average True Range (ATR)
- TENX 0.24
- LGVN 0.15
- MACD
- TENX -0.04
- LGVN -0.11
- Stochastic Oscillator
- TENX 7.22
- LGVN 3.90
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.